EP4153785A1 - Procédé de pcr en temps réel isotherme pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon - Google Patents

Procédé de pcr en temps réel isotherme pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon

Info

Publication number
EP4153785A1
EP4153785A1 EP21731167.9A EP21731167A EP4153785A1 EP 4153785 A1 EP4153785 A1 EP 4153785A1 EP 21731167 A EP21731167 A EP 21731167A EP 4153785 A1 EP4153785 A1 EP 4153785A1
Authority
EP
European Patent Office
Prior art keywords
sequence
primer
sample
rna
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21731167.9A
Other languages
German (de)
English (en)
Inventor
Samuel Zürcher
Alexander Lüthi
Lea Weibel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ender Holding Ag
Original Assignee
Ender Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ender Holding Ag filed Critical Ender Holding Ag
Publication of EP4153785A1 publication Critical patent/EP4153785A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Definitions

  • the present invention relates to a method for determining presence of a pre-determined RNA sequence in a sample, the method comprising the steps of adding one or more enzyme(s) providing activities of RNA- and DNA-dependent DNA polymerase activity and strand- displacement activity to the sample to be analysed for the presence of the pre-determined RNA sequence; simultaneously or subsequently adding at least five DNA primers to the sample to be analysed for the presence of the pre-determined RNA sequence, wherein at least one DNA primer comprises a sequence hybridisable to the RNA sequence and at least one DNA primer comprises a sequence hybridisable to the DNA sequence reverse-complementary to the RNA sequence; incubating the sample resulting from the previous steps at a fixed temperature; and determining whether an elongated double-stranded DNA sequence is present in the sample, wherein presence of the elongated double-stranded DNA sequence in the sample is indicative of the presence of the pre-determined RNA sequence in the sample wherein the pre-determined RNA sequence is part of an RNA virus and wherein no F
  • RNA sequences there are various methods directed at detecting the presence of RNA sequences in samples.
  • most of the known techniques require a substantial amount of time.
  • time is a limiting factor.
  • coronaviruses in wild animal populations, but only a few developed the ability to infect humans, comprising SARS-CoV, MERS-CoV and the newly emerging SARS-CoV-2. All of them can cause severe respiratory, gastrointestinal, and central nervous system diseases.
  • a coronavirus infection is not recognized by the patient or is recognized as a common cold.
  • the incubation time of coronaviruses before symptoms develop is about 4 days to 2 weeks. This makes it challenging for health-care systems to follow viral spread.
  • available molecular virus tests take several hours to provide a reliable result and have to be performed at a centralized laboratory. During this time, the potentially infected person may have already infected other persons, further spreading the virus.
  • RNA in particular viral RNA, more particular RNA derived from a corona virus, in a sample.
  • the present invention relates to the following embodiments.
  • a method for determining presence of a pre-determined RNA sequence in a sample comprising the steps of:
  • the method of embodiment 1, wherein four of the at least five primers are forward inner primer (FIP), backward inner primer (BIP), loop primer forward (LPF) and loop primer backwards (LPB), respectively.
  • the enzyme having RNA- dependent DNA polymerase activity is a reverse transcriptase enzyme or a DNA polymerase with reverse transcriptase activity and, optionally, strand displacement activity.
  • the method of any one of embodiments 1 to 4 wherein the RNA virus is a single-stranded RNA virus.
  • the method of embodiment 5, wherein the RNA virus is a coronavirus.
  • the method of embodiment 6, wherein the coronavirus (CoV) is of the genus ⁇ -CoV, ⁇ -
  • coronavirus is selected from the group consisting of Human coronavirus OC43 (HCoV-OC43), Human coronavirus HKU1 (HCoV-HKUl), Human coronavirus 229E (HCoV-229E), Human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), Middle East respiratory syndrome-related coronavirus (MERS-CoV or "novel coronavirus 2012"), Severe acute respiratory syndrome coronavirus (SARS-CoV or "SARS-classic”), and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or "novel coronavirus 2019”).
  • HKU1 HoV-HKUl
  • HCV-229E Human coronavirus NL63
  • MERS-CoV or "novel coronavirus 2012 Middle East respiratory syndrome-related coronavirus
  • Severe acute respiratory syndrome coronavirus SARS-CoV or "SARS-classic
  • the method of any one of embodiments 1 to 10, wherein the virus is a corona virus and one or more of the primers comprise the following sequences:
  • FIP primer sequence CTT GCT CTT CTT CAG GTT GAC CAA GGT AAA CCT TTG; and/or
  • BIP primer sequence GGT TAG ATG ATG ATA GTC CTG ATT GTC CTC ACT GCC; and/or
  • LPF primer sequence AAG AGC AGC AGA AGT GGC AC;
  • LPB primer sequence CAA ACT GTT GGT CAA CAA G;
  • B3 primer sequence GAA CCT CAA CAA TTG TTT GAA TAG.
  • the invention relates to a method for determining presence of a pre-determined RNA sequence in a sample, the method comprising the steps of adding one or more enzyme(s) providing activities of RNA- and DNA-dependent DNA polymerase activity and strand-displacement activity to the sample to be analysed for the presence of the pre- determined RNA sequence; simultaneously or subsequently adding at least five DNA primers to the sample to be analysed for the presence of the pre-determined RNA sequence, wherein at least one DNA primer comprises a sequence hybridisable to the RNA sequence and at least one DNA primer comprises a sequence hybridisable to the DNA sequence reverse-complementary to the RNA sequence; incubating the sample resulting from the previous steps at a fixed temperature; and determining whether an elongated double-stranded DNA sequence is present in the sample, wherein presence of the elongated double-stranded DNA sequence in the sample is indicative of the presence of the pre-determined RNA sequence in the sample wherein the pre-determined RNA sequence is part of
  • pre-determined RNA sequence refers to an RNA sequence, where the skilled person is aware that it is part of an RNA virus.
  • the pre-determined RNA sequence within the present invention, is a sequence that is detectable using the method of the present invention. That is, an RNA sequence available to the skilled person is pre- determined if the skilled person can determine whether the sequence will likely be detectable in a sample using the methods as provided herein.
  • the pre- determined RNA sequence comprises at least one primer binding site that is at least partially identical to at least one of the primers used in the methods of the invention.
  • Primer binding sites are considered identical to a primer site if the sequence is exactly identical or if they differ only in that one sequence comprises uracil instead of thymidine and/or if they differ only in that one sequence comprises one or more modified nucleotides instead of the respective non-modified nucleotide(s).
  • DNA primer refers to a nucleic acid molecule comprising a 3 '-terminal -OH group that, upon hybridisation to a complementary nucleic acid sequence, can be elongated, e.g., via an enzymatic nucleic acid replication reaction.
  • the primer set according to the present invention is used for amplification of nucleic acids, that is, for a LAMP analysis or a RT-LAMP analysis. Both the upper and lower limits of the length of the primer are empirically determined.
  • the DNA primer described herein can be a forward primer or a backward primer.
  • backward primer refers to a primer priming the antisense strand of a DNA sequence to allow the polymerase to extend in one direction along the complementary strand of a DNA sequence. At least one backward primer also serves as the RT primer for reverse transcription.
  • forward primer refers to a primer priming the sense strand of a DNA sequence to allow a polymerase to extend in one direction along one strand of a DNA sequence.
  • sample refers to any specimen potentially comprising the pre- determined RNA sequence.
  • a sample as used in the methods of the present invention can be derived from a living body (e.g., plants, and/or animals, preferably humans, such as, bronchoalveolar lavage, bronchial wash, pharyngeal exudate, tracheal aspirate, blood, serum, plasma, bone, skin, soft tissue, intestinal tract specimen, genital tract specimen, breast milk, lymph, cerebrospinal fluid, pleural fluid, sputum, urine, a nasal secretion, tears, bile, ascites fluid, pus, synovial fluid, vitreous fluid, vaginal secretion, semen and/or urethral tissue), primary- or modified cells, tissue, cell cultures, culture medium, additives, cell derived products, laboratory equipment, biopharmaceutical products, microorganisms and/or samples separated, for example, from food, soil and/or waste-water.
  • a living body e.g
  • Isolation of pre-determined RNA sequence from the initial sample can be carried out by any method known to the person skilled in the art, such as, e.g., lysis treatment with a surfactant, sonic treatment, shaking agitation using glass beads or a French press method.
  • an endogenous nuclease may be used to reduce the length of nucleic acid molecules.
  • purification of the nucleic acid may be performed by, for example, phenol extraction, chromatography, ion exchange, gel electrophoresis, density-dependent centrifugation and/or other methods known to the person skilled in the art.
  • RNA- and DNA-dependent DNA polymerase activity can synthesize DNA in the 5 '->3' direction based on a template composed of a DNA or RNA strand.
  • an enzyme will be successively adding nucleotides to the free 3 '-hydroxyl group of the template.
  • the template strand determines the sequence of the added nucleotides based on Watson-Crick base pairing.
  • the activity of the DNA polymerase may be RNA- and/or DNA-dependent.
  • Exemplary polymerases include, but are not limited to Bst DNA polymerase, Vent DNA polymerase, Vent (exo-) DNA polymerase, Deep Vent DNA polymerase, Deep Vent (exo-) DNA polymerase, Bca (exo-) DNA polymerase, DNA polymerase I Klenow fragment, F29 phage DNA polymerase, Z-TaqTM DNA polymerase, ThermoPhi polymerase, 9°Nm DNA polymerase, and KOD DNA polymerase. See, e.g., U.S. Pat. Nos. 5,814,506; 5,210,036; 5,500,363; 5,352,778; and 5,834,285; Nishioka, M., et al. (2001) J. Biotechnol. 88, 141; Takagi, M., et al. (1997) Appl. Environ. Microbiol. 63, 4504.
  • any suitable reverse transcriptase may be employed.
  • the enzyme to be used is not particularly limited, with the proviso that it has the activity to synthesize cDNA using RNA as the template.
  • a substance which improves heat resistance of the nucleic acid amplification enzyme such as trehalose, can be added.
  • strand displacement refers to the ability of an enzyme to separate the DNA and/or RNA strands in a double-stranded DNA molecule and/or in a double-stranded RNA molecule during primer-initiated synthesis.
  • hybridisation refers to the annealing of complementary nucleic acid molecules.
  • the two nucleic acid molecules exhibit a sufficient number of complementary nucleobases that the two nucleic acid molecules can anneal to each other under the particular conditions (e.g. , temperature, salt and other buffer conditions) being utilized for a particular reaction.
  • the most common mechanism of hybridisation involves hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary nucleobases of the nucleic acid molecules.
  • Hybridisation can occur under varying conditions.
  • Nucleic acid hybridisation techniques and conditions are known to the skilled artisan and have been described extensively. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual 2nd ed.. Cold Spring Harbor Press, 1989; Ausubel et al, 1987, Current Protocols in Molecular Biology; Greene Publishing and Wiley-Interscience, New York; Tijessen, 1993, Hybridization with Nucleic Acid Probes, Elsevier Science Publishers, B.V.; and Kricka, 1992, Non-Isotopic DNA Probe Techniques, Academic Press, San Diego, California.
  • F3 refers to the outer forward primer of a primer set.
  • a five-primer system wherein the F3 primer is omitted is most efficient in detecting a pre-determined RNA sequence.
  • “Most efficient” as used herein means that detection is faster and more sensitive than commonly used techniques but maintains reliability, which is a prerequisite in tests used for detecting viral infection.
  • the invention provides a sample containing a pre-determined RNA sequence, and a method for amplifying a nucleic acid, which comprises carrying out an amplification reaction of the pre- determined RNA sequence in the sample, in a reaction system wherein at least one primer of the invention is present.
  • At least one species of the primers is used in the nucleic acid amplification reaction of the invention. That is, the DNA primer described herein may be used in combination with other primers, or two species of the DNA primer described herein may be used.
  • the at least two of the primers employed in the invention are loop primers.
  • loop primer refers to a DNA primer comprising a sequence that is hybridisable to at least one loop region of an amplification product of the pre-determined RNA sequence.
  • the loop region is formed by the annealing of a strand of an amplification product to itself.
  • loop primers hybridise to generated DNA sequences and provide an increased number of starting points for the initiation of further DNA elongation processes.
  • the use of loop primer can accelerate the amplification process.
  • four of the at least five primers are forward inner primer (FIP), backward inner primer (BIP), loop primer forward (LPF) and loop primer backwards (LPB), respectively.
  • FIP forward inner primer
  • forward primer refers to a forward primer that comprises a sequence for strand initiation and a sequence hybridisable to the same FIP -initiated strand.
  • BIP backward inner primer
  • backward primer refers to a backward primer that comprises a sequence for strand initiation and a sequence hybridisable to the same BIP -initiated strand.
  • loop primer forward refers to a loop primer that is a forward primer.
  • loop primer backwards refers to a loop primer that is a backwards primer.
  • the fifth primer is a B3 primer.
  • the DNA Primer described herein that specifically binds to a target nucleic acid or its complementary sequence may be at least 10, 15, or 19 nucleotides in length, at least 18, 20, 22 or 24 nucleotides for B3, at least 25, 30, 33, or 36 nucleotides for FIP and BIP, and at least 10, 15, 17, or 19 for LPF and LPB.
  • DNA Primers that specifically bind to a target nucleic acid sequence may have a nucleic acid sequence at least 80% complementarity, particularly 90% complementarity, more particularly 95%, 96%, 97%, 98%, 99% or 100% complementarity with the corresponding region.
  • no F3 primer is used. This is because it was surprisingly found by the inventors that in the presence of a B3 primer but absence of an F3 primer, detection is faster and more sensitive. Using the methods of the present invention, detection was observed to be possible within ten minutes and more sensitive to detect a low number of pre-determined RNA sequence in a sample. That is, as it is shown in the appended Examples, a positive detection of a pre-determined RNA sequence of a corona virus was achieved using five primers, in particular FIP, BIP, LPF, LPB and B3, within ten minutes after addition of primers and enzymes. Accordingly, the methods of the present invention, for the first time, provide a reliable and fast way to detect viral infections which is important in controlling a pandemic outbreak of the same.
  • one or more enzyme(s) providing activities of RNA- and DNA-dependent DNA polymerase activity and strand-displacement activity are used. That is, all three activities are to be added to the RNA sequence to be analyzed.
  • the activities can be provided by one enzyme having all three activities, or several enzymes each having one or more of the three activities.
  • the RNA virus comprising the pre-determined RNA sequence is a coronavirus.
  • the RNA virus may be of any kind.
  • RNA virus refers any virus that uses RNA as its genetic material.
  • the RNA virus may be a virus selected from the group of dsRNA virus, positive-sense ssRNA virus and negative-sense ssRNA virus.
  • the RNA virus may be a virus selected from the group of Amalgaviridae, Birnaviridae, Chrysoviridae, Cystoviridae, Endomaviridae, Hypoviridae, Megabirnaviridae, Partitiviridae, Picobimaviridae, Reoviridae, Totiviridae, Quadriviridae, Botybirnavirus, Unassigned dsRNA viruses, Arteriviridae, Coronaviridae (includes inter alia Coronavirus, SARS-CoV), Mesoniviridae, Roniviridae, Dicistroviridae, Iflaviridae, Mamaviridae, Picornaviridae, Secoviridae, Alphaflexiviridae, Betaflexiviridae, Gammaflexiviridae, Tymoviridae, Alphatetraviridae, Alvernaviridae, Astroviridae, Barnaviridae
  • the Coronavirus may in particular be of the genus ⁇ -CoV, ⁇ -CoV, ⁇ -CoV or ⁇ -CoV. More particularly, the Coronavirus may be selected from the group consisting of Human coronavirus OC43 (HCoV-OC43), Human coronavirus HKU1 (HCoV- HKU1), Human coronavirus 229E (HCoV-229E), Human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), Middle East respiratory syndrome-related coronavirus (MERS-CoV or "novel coronavirus 2012"), Severe acute respiratory syndrome coronavirus (SARS-CoV or "SARS- classic”), and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or "novel coronavirus 2019”).
  • HKU1 Human coronavirus HKU1
  • HoV-229E Human coronavirus NL63
  • MERS-CoV or "novel coronavirus 2012 Middle East
  • the RNA-virus described herein is a variant having an at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% sequence identity to the viral genome sequence of at last one RNA-virus described herein.
  • the SARS-CoV-2 described herein is a SARS-CoV-2 variant.
  • the SARS-CoV-2 variant described herein is a SARS-CoV-2 variant selected from the group of Lineage B.1.1.207, Lineage B.1.1.7, Cluster 5, 501.V2 variant, Lineage P.1, Lineage B.1.429 / CAL.20C, Lineage B.1.427, Lineage B.1.526, Lineage B.1.525, Lineage B.1.1.317, Lineage B.1.1.318, Lineage B.1.351, Lineage B.1.617 and Lineage P.3.
  • the SARS-CoV-2 variant described herein is a SARS-CoV-2 variant described by a Nextstrain clade selected from the group 19 A, 20 A, 20C, 20G, 20H, 20B, 20D, 20F, 201, and 20E.
  • the SARS-CoV-2 virus described herein is a SARS- CoV-2 variant comprising at least one mutation selected from the group of D614G, E484K, N501Y, S477G/N, P681H, E484Q, L452R and P614R.
  • the SARS-CoV- 2 variant described herein is a SARS-CoV-2 variant or a hybrid derived from the variants described herein.
  • step (c) thereof the temperature can be fixed.
  • the term "fixed temperature”, as used herein, refers to keeping the temperature condition constant or almost constant so that enzymes and primers can substantially function.
  • the almost constant temperature condition means that not only the set temperature is accurately maintained but also a slight change in the temperature is acceptable within such a degree that it does not spoil substantial functions of the enzymes and primers. For example, a change in temperature of approximately from 0 to 10°C is acceptable.
  • the nucleic acid amplification reaction under a fixed temperature can be carried out by keeping the temperature at such a level that activity of the enzyme to be used can be maintained.
  • to set the reaction temperature may be set to the temperature of around the Tm value of the primer or lower than that, and it is preferred to set it at a level of stringency by taking the Tm value of the primer into consideration.
  • the amplification reaction can be repeated until the enzyme is inactivated or one of the reagents including primers is used up.
  • the one or more enzyme(s), DNA primers and the sample to be analyzed are incubated in the same tube at a constant temperature.
  • the temperature is preferably between 50 and 75°C. However, the temperature may also be lower, for example between 30 and 75°C.
  • a touchdown temperature step is used. That is, the temperature is lowered during the course of the analysis, for example starting at a temperature of 70°C that is subsequently lowered to 50°C.
  • the one or more enzyme(s), DNA primers and the sample to be analyzed are incubated in the same tube for a time between 1 and 120 minutes, preferably between 1 and 60, 1 and 45, 1 and 30 or between 1 and 15 minutes.
  • the sample is incubated for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 minutes.
  • the virus is a corona virus.
  • the preferred primer sequences are shown below:
  • FIP primer sequence CTT GCT CTT CTT CAG GTT GAC CAA GGT AAA CCT TTG (SEQ ID NO: 1); and/or
  • BIP primer sequence GGT TAG ATG ATG ATA GTC CTG ATT GTC CTC ACT GCC (SEQ ID NO: 2);
  • LPF primer sequence AAG AGC AGC AGA AGT GGC AC (SEQ ID NO: 3);
  • LPB primer sequence CAA ACT GTT GGT CAA CAA G (SEQ ID NO: 4);
  • B3 primer sequence GAA CCT CAA CAA TTG TTT GAA TAG (SEQ ID NO: 5).
  • the above primer sequences target a sequence of corona virus.
  • the above primer target the following sequence
  • the primers used in the methods of the invention comprise at least one selected from the group of: a) a FIP primer comprising a sequence that has at least 88%, 91%, 94%, 97% or 100% sequence identity to the sequence: SEQ ID NO: 1, which sequence still provides the primer functionality, b) a BIP primer comprising a sequence that has at least 88%, 91%, 94%, 97% or 100% sequence identity to the sequence: SEQ ID NO: 2, which sequence still provides the primer functionality, c) a LPF primer comprising a sequence that has at least 85%, 90%, 95%, or 100% sequence identity to the sequence: SEQ ID NO: 3, which sequence still provides the primer functionality, d) a LPB primer comprising a sequence that has at least 84%, 89%, 94%, or 100% sequence identity to the SEQ ID NO: 4, which sequence still provides the primer functionality, and e) a B3 primer comprising a sequence that has at least 83%, 87%, 91%
  • the primers used in the methods of the invention comprise at least one primer providing primer functionality at a coronavirus genome, in particular at the SARS-CoV- 2 genome and having a sequence with at least 85%, 90%, 95%, or 100% sequence identity to a sequence selected from the group of: SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 32
  • the primers used in the methods of the invention comprise at least one primer providing primer functionality at a coronavirus genome, in particular at the SARS-CoV- 2 genome and having a sequence with at least 85%, 90%, 95%, or 100% sequence identity to a sequence selected from the group of: a) SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24 or SEQ ID NO: 25, b) SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30 or SEQ ID NO: 31, c) SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 32, SEQ
  • Percent (%) sequence identity with respect to a reference sequence is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • the methods of the present invention comprise a step of determining whether an elongated double-stranded DNA sequence is present in the sample, in particular wherein presence of the elongated double-stranded DNA sequence in the sample is indicative of the presence of the pre- determined RNA sequence in the sample.
  • the skilled person is well-aware of methods suitable to be used for determining presence of an elongated double-stranded DNA sequence in a sample, in particular where the sequence to be detected is known. Thus, any method known to the skilled person for that purpose may be used within the present invention.
  • the presence of the elongated double-stranded DNA is determined by using a molecule that intercalates in the elongated double-stranded DNA and thereby starts fluorescing which can be detected and quantified with specialised equipment.
  • Other methods such as using a nucleic acid molecule hybridisable to the elongated double-stranded DNA sequence, in particular wherein the nucleic acid molecule is labelled or bound to a surface, or using turbidity measurement of the enzyme reaction can be used to determine the elongation of the DNA.
  • label refers to any detectable or signal-generating molecule or reporter molecule.
  • Convenient labels include colorimetric, chemiluminescent, chromogenic, radioactive and fluorescent labels, but enzymatic (e.g. colorimetric, luminescent, chromogenic) or antibody-based labelling methods or signal- generating systems may also be used.
  • label as used herein includes not only directly detectable signal-giving or passive moieties, but also any moiety which generates a signal or takes part in a signal generating reaction or that may be detected indirectly in some way.
  • label refers to being connected with or linked to a detectable label.
  • Determining whether an elongated double-stranded DNA sequence is present in the sample may be achieved via fluorescence reporting.
  • the majority of such approaches are based on the use of intercalating dyes, such as ethidium bromide, SYBR Green, EvaGreen and YO-PRO-I (Zhang X, et al. 2013, PLoS One 8(12):e82841; Mair G. et al. 2013, BMC Veterinary Research 9: 108.).
  • an agent or dye that “intercalates” refers to an agent or moiety capable of non-covalent insertion between stacked base pairs in a nucleic acid double helix.
  • Determining whether an elongated double-stranded DNA sequence is present in the sample may be achieved by a Fluorescence technique that relies on the mechanism of Forster resonance energy transfer (FRET) (Chen Q, et al., 1997, Biochemistry 36(15):4701- 11).
  • FRET Forster resonance energy transfer
  • the LPB and/or EPF are labelled at the 5’ end with at least one label and/or acceptor fluorophore.
  • turbidity refers to a measure of the suspended and/or soluble particles in a fluid or transparent solid that causes light to be scattered or absorbed.
  • indirect determination of whether an elongated double-stranded DNA sequence is present in the sample relies essentially on the formation of pyrophosphate as a reaction byproduct.
  • Pyrophosphate ions can be released by incorporation of deoxynucleotide triphosphates (dNTPs) into the DNA strand during nucleic acid polymerization and these ions react with divalent metal ions, particularly magnesium ions, present in the reaction mix to produce a white, insoluble magnesium pyrophosphate precipitate as described by Mori Y., et al.
  • determining whether an elongated double-stranded DNA sequence is present in a sample is achieved through the incorporation of manganese ions and calcein in the reaction. Calcein's fluorescence is naturally quenched by binding of manganese ions.
  • Pyrophosphate production as a reaction byproduct removes manganese ions form the buffer through precipitation, and the increased turbidity coupled with restored calcein fluorescence enables an easy visual read-out upon excitation with either visible or UV light (Tomita N., et al. 2008. Nat. Protoc. 3:877-882).
  • the enzymatic conversion of pyrophosphate into ATP is monitored through the bioluminescence generated by thermostable firefly luciferase for determining whether an elongated double-stranded DNA sequence is present in the sample (Gandelman OA., et al. 2010, PLoS One 5(11): el4155).
  • the present invention further relates to a method of treating a patient infected by a virus of the corona family, in particular Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising administering to the patient an efficient amount of antiviral treatment, wherein the patient has previously been determined to be infected by a virus of the corona family using the method of the present invention.
  • antiviral treatment comprises administering an efficient amount of Remdesivir to the patient.
  • the invention relates to a method of treating a patient infected by a virus of the corona family, in particular Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising administering to the patient an efficient amount of antiviral treatment, wherein the patient has previously been determined to be infected by a virus of the corona family using the method of the invention.
  • SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
  • the invention relates to an antiviral compound for use in the treatment of a patient, wherein the patient has previously been determined to be infected by a virus of the corona family, in particular Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), using the method of the invention.
  • a virus of the corona family in particular Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
  • antiviral compound refers to a compound that has an effect on a virus and/or on symptoms of a virus-related disease.
  • the effect on a virus may include, inter alia, properties of preventing, inhibiting, suppressing, reducing, adversely impacting, and/or interfering with the growth, survival, replication, function, and/or dissemination of a virus.
  • the antiviral compound is selected from the group of vaccine, immunomodulator, cardiovascular modulator, lung-function modulator and viral replication inhibitor.
  • the antiviral compound is at least one compound selected from the group of darunavir, oseltamivir, umifenovir, favipiravir, ribavirin, nafamostat mesylate, camostat mesylate, lopinavir, ritonavir, nelfmavir, teicoplanin, azithromycin, chloroquine, hydroxy chloroquine, thalidomide, bevacizumab, tocilizumab, sarilumab, anakinra, interferon ( ⁇ , ⁇ , X), losartan, corticosteroid (e.g. methylprednisolone), ivermectin, nitazoxanide, emetine, famotidin, heparin, EIDD-2801 and dipyridamole.
  • the group of darunavir oseltamivir, umifenovir, favipira
  • treatment refers to a clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
  • the term “patient”, as used herein, refers to animals, including mammals, preferably humans.
  • the patient described herein has a predisposition that increases the risk of an adverse disease progression upon viral infection.
  • the redisposition that increases the risk of an adverse disease progression upon viral infection is a condition selected from the group of cancer, chronic kidney disease, chronic lung diseases (e.g. COPD, asthma, interstitial lung disease, cystic fibrosis, and pulmonary hypertension, emphysema, chronic bronchitis, damaged or scarred lung tissue, interstitial lung disease), pulmonary hypertension, neurological conditions (e.g. dementia, Alzheimer’ s), diabetes, down syndrome, heart conditions (e.g.
  • heart failure coronary artery disease, cardiomyopathies or hypertension
  • HIV infection immunocompromised state
  • liver disease overweight, obesity, pregnancy, sickle cell disease, thalassemia, smoking, , solid organ transplant, blood stem cell transplant, stroke, cerebrovascular disease and substance use disorders.
  • Remdesivir refers not only to the drug itself but also to active metabolites of the drug and any pharmaceutical composition thereof. In a preferred embodiment of the invention, Remdesivir can be injected and/or inhaled.
  • the patient that has previously been determined to be infected by a virus of the corona family using the method of the invention may benefit from an early treatment, e.g., preventive treatment before the onset of (severe) symptoms.
  • the invention relates to an antiviral compound for use in the treatment of a patient, wherein the patient has previously been determined not to be infected by a virus of the corona family using the method of the invention, preferably wherein the antiviral compound is a vaccine.
  • the method of the invention can efficiently determine the pathogen efficiently and facilitates early detection, screening, monitoring, and/or confirmation of a past infection. This facilitated detection can improve the treatment of an infection, reduce pathogen spreading and/or avoid disease progression
  • the invention enables the determination of subjects that benefit particularly from an antiviral treatment and the improvement of the antiviral treatment.
  • the kit can be prepared by collecting necessary reagents.
  • the invention relates to a kit, in particular a kit for use in detecting viral RNA in a sample.
  • the kit comprises one or more, preferably all five or six primers for detecting a pre-determined RNA sequence.
  • the kit may comprises (an) enzyme(s) providing RNA and/or DNA polymerase activity and strand-displacement activity, nucleic acid synthases, dNTP, a buffer, a melting temperature adjusting agent, a reaction container and specifications.
  • the kit may also comprise more than one primer system, in particular two or more primer systems targeting different sequences of the same RNA virus, e.g. by using primers that contain a quencher-fluorophore duplex region (Tanner NA, Zhang Y, Evans TC Jr. Simultaneous multiple target detection in real-time loop-mediated isothermal amplification. Biotechniques. 2012;53(2):81-89.).
  • a kit may be particularly useful by simultaneous detection of several medical conditions and/or the detection of several RNA viruses or several variants of viruses. In this regard, it was surprisingly found that the reduced number of primers leads to an improved usability of more than one primer systems due to reduced primer interference.
  • kits (to be prepared in context) of this invention or the methods and uses of the invention may further comprise or be provided with (an) instruction manual(s).
  • said instruction manual(s) may guide the skilled person (how) to employ the kit of the invention in the diagnostic uses provided herein and in accordance with the present invention.
  • said instruction manual(s) may comprise guidance to use or apply the herein provided methods or uses.
  • Figure 2 shows the time after which signal is determined using the 5 primer system and the 6 primer system.
  • the novel 5 primer system without F3 amplifies SARS-CoV2 RNA as efficient as 6 primer system with F3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé pour déterminer la présence d'une séquence d'ARN prédéterminée dans un échantillon, le procédé comprenant les étapes suivantes : ajout d'une ou plusieurs enzymes fournissant des activités d'activité d'ADN polymérase dépendante de l'ARN et de l'ADN et une activité de déplacement de brin à l'échantillon à analyser pour la présence de la séquence d'ARN prédéterminée ; ajout simultané ou ultérieur d'au moins cinq amorces d'ADN à l'échantillon à analyser pour la présence de la séquence d'ARN prédéterminée, au moins une amorce d'ADN comprenant une séquence hybridable à la séquence d'ARN et au moins une amorce d'ADN comprenant une séquence hybridable à la séquence d'ADN complémentaire inverse de la séquence d'ARN ; incubation de l'échantillon résultant des étapes précédentes à une température fixe ; et détermination de la présence d'une séquence d'ADN double brin allongée dans l'échantillon, la présence de la séquence d'ADN double brin allongée dans l'échantillon étant indicative de la présence de la séquence d'ARN prédéterminée dans l'échantillon, la séquence d'ARN prédéterminée faisant partie d'un virus à ARN et aucune amorce F3 n'étant utilisée.
EP21731167.9A 2020-06-09 2021-06-09 Procédé de pcr en temps réel isotherme pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon Withdrawn EP4153785A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20179109.2A EP3922734A1 (fr) 2020-06-09 2020-06-09 Procédé pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon
PCT/EP2021/065549 WO2021250140A1 (fr) 2020-06-09 2021-06-09 Procédé de pcr en temps réel isotherme pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon

Publications (1)

Publication Number Publication Date
EP4153785A1 true EP4153785A1 (fr) 2023-03-29

Family

ID=71083454

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20179109.2A Withdrawn EP3922734A1 (fr) 2020-06-09 2020-06-09 Procédé pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon
EP21731167.9A Withdrawn EP4153785A1 (fr) 2020-06-09 2021-06-09 Procédé de pcr en temps réel isotherme pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20179109.2A Withdrawn EP3922734A1 (fr) 2020-06-09 2020-06-09 Procédé pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon

Country Status (7)

Country Link
EP (2) EP3922734A1 (fr)
JP (1) JP2023538180A (fr)
KR (1) KR20230035317A (fr)
CN (1) CN116134156A (fr)
AU (1) AU2021288610A1 (fr)
CA (1) CA3181838A1 (fr)
WO (1) WO2021250140A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500363A (en) 1990-04-26 1996-03-19 New England Biolabs, Inc. Recombinant thermostable DNA polymerase from archaebacteria
US5210036A (en) 1990-04-26 1993-05-11 New England Biolabs, Inc. Purified thermostable DNA polymerase obtainable from thermococcus litoralis
US5352778A (en) 1990-04-26 1994-10-04 New England Biolabs, Inc. Recombinant thermostable DNA polymerase from archaebacteria
US5814506A (en) 1995-08-02 1998-09-29 New England Biolabs, Inc. Over-expression and purification of a truncated thermostable DNA polymerase by protein fusion
JP5740112B2 (ja) * 2010-07-26 2015-06-24 株式会社東芝 コロナウイルスのためのｌａｍｐ増幅用核酸プライマーセット
WO2018089943A1 (fr) * 2016-11-10 2018-05-17 Slipchip Corporation Détection de sonde de produits d'amplification à médiation par boucle
CN111206120A (zh) * 2020-03-20 2020-05-29 江苏奇天基因生物科技有限公司 一种检测新型冠状病毒SARS-CoV-2的引物探针组及检测方法

Also Published As

Publication number Publication date
EP3922734A1 (fr) 2021-12-15
CA3181838A1 (fr) 2021-12-16
WO2021250140A1 (fr) 2021-12-16
AU2021288610A1 (en) 2023-01-19
JP2023538180A (ja) 2023-09-07
KR20230035317A (ko) 2023-03-13
CN116134156A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
JP7114676B2 (ja) Ｒｎａウイルスを検出するための組成物及び方法
ES2743050T3 (es) Composiciones y procedimientos para cuantificar una secuencia de ácido nucleico en una muestra
US7595163B2 (en) Method for detecting SARS coronavirus
JP7313537B2 (ja) コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）の検出方法
CN107022651A (zh) 一种快速检测丙型肝炎病毒核酸的试剂盒及其检测方法
CN116171333A (zh) 用于检测严重急性呼吸综合征冠状病毒2(sars-cov-2)、甲型流感和乙型流感的组合物和方法
CN117529560A (zh) 检测微小rna的方法和试剂盒
JP2022191442A (ja) 非特異的な核酸増幅を抑制する方法
TWI377255B (en) Nucleic acid detection
US20200377928A1 (en) Method of detecting minor bcr-abl1 gene
EP4153785A1 (fr) Procédé de pcr en temps réel isotherme pour déterminer la présence d'une séquence d'arn prédéterminée dans un échantillon
CN115852056A (zh) 呼吸道病毒检测的荧光pcr试剂盒及检测方法
TWI723675B (zh) 用於檢測登革熱病毒的方法以及套組
CN115989323A (zh) 检测SARS-CoV-2感染的方法
JP2007000040A (ja) Ｂ型肝炎ウイルスの検出方法
KR20080111785A (ko) 수인성 바이러스를 검출하기 위한 중합효소연쇄반응의프라이머 및 프로브, 및 이를 이용한 검출키트 및 방법
JP2022501073A (ja) 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法
CN105018577B (zh) 硫柳汞在荧光定量pcr中的应用
JP2023098185A (ja) 標的塩基配列の検出方法
WO2024058680A1 (fr) Ensemble d'amorces, composition du mélange réactionnel et procédé de détection des types a et b du virus respiratoire syncytial humain (rsva et rsvb)
JP2007306817A (ja) Ｒｓウイルスを検出するためのポリヌクレオチド及びこれを用いた検出方法
KR20130102431A (ko) Ａ형 인플루엔자 ｈ１ｎ１ 바이러스 검출용 키트

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230725